Krystal Biotech reports Q3 beat and authorizes $400 million buyback
On Nov. 2, Krystal Biotech reported third-quarter 2026 revenue of $127.34M and EPS of $2.05, with revenue up 30.2% year over year. The board approved a buyback of up to $400 million, while the company said German and Italian VYJUVEK pricing negotiations had concluded and that Italy's launch is expected in early 2027. Management also lowered adjusted expense guidance to $155M-$165M and said some pipeline readouts would move to 2027.
Why it matters
The results add cash-return capacity through the buyback and provide more visibility on VYJUVEK's European rollout. Delayed pipeline readouts and slower enrollment in some studies may leave investors focused on execution beyond the reported earnings beat.
Key facts
- 1Krystal Biotech reported third-quarter revenue of $127.34M and EPS of $2.05, with revenue increasing 30.2% year over year. tradingview.com
- 2The board authorized a share repurchase program of up to $400 million, which the company expects to deploy over the next 2 years. finance.yahoo.com
- 3VYJUVEK pricing negotiations finished in Germany and Italy, and the company expects to launch in Italy in early 2027. stocktitan.net
- 4Management guided adjusted expenses to $155M-$165M. finance.yahoo.com
- 5The company expects top-line results from the KB801 EMERALD-1 study in 2027 after enrollment progressed more slowly than initially anticipated. stocktitan.net
Open questions
- Material 6 reports Q3 revenue of $1.1B, while materials 3 and 5 report $127.34M; material 11 describes approximately $1.1 billion as cumulative VYJUVEK revenue since launch, so the $1.1B Q3 figure is not reconciled.
- The reported EPS beat differs by source, at $0.21 in material 3 versus $0.28 in material 6.
Summary written by AlphAI AI Desk from 13 of 13 sources. Not investment advice. Figures are as stated by the linked sources.